Skip to main content
logo
SolarWinds Corporation (SWI)
Apr 16, 2025 - SWI was delisted (reason: acquired by Turn/River)
18.49
0.00 (0.00%)
Inactive · Last trade price on Apr 15, 2025

Revance Therapeutics Revenue

In the year 2024, SolarWinds had annual revenue of $796.90M with 5.03% growth. SolarWinds had revenue of $210.31M in the quarter ending December 31, 2024, with 6.14% growth.

Revenue (ttm)
$796.90M
Revenue Growth
+5.03%
P/S Ratio
3.93
Revenue / Employee
$378,213
Employees
2,107
Market Cap
3.17B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2024796.90M38.16M5.03%
Dec 31, 2023758.74M39.37M5.47%
Dec 31, 2022719.37M735.00K0.10%
Dec 31, 2021718.63M1.86M0.26%
Dec 31, 2020716.77M47.67M7.12%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

SWI News

More News